31 October 2017
The Multiple Sclerosis team has been working with a New Zealand biomedical company that has developed a microparticle that could be used to regulate immune responses.
Their research is looking at how this microparticle harnesses the body’s natural reparatory pathways by targeting very specific innate cell types, and how this might be used to repair neurons damaged by progressive forms of MS.
The results of the work have recently been submitted for publication following human clinical trials and an exploratory trial.
“We’ve been looking at how the microparticle affects disease in much larger populations and if there are any correlations with protection. This will help us identify those who may bene t from this treatment,” says head of the MS team, Professor Anne La Flamme.